Why Did WOK Stock Skyrocket Nearly 300% In Just 2 Days?

• On Monday, Work Medical announced a partnership with Shanghai Novabioplus Biotechnology to develop AI-powered healthcare and drug discovery systems.
• The deal includes AI-based projects involving protein design, antibody optimization, enzyme engineering and peptide development.
• Investors also focused on the company’s new “BioToken” concept, which involves creating blockchain-based digital biological assets.

Shares of Work Medical Technology Group (WOK) skyrocketed nearly 300% so far this week after the China-based medical device company announced an AI biotech partnership and expanded its push into blockchain-based healthcare infrastructure.

WOK stock surged more than 200% on Monday after the partnership announcement and gained another 70% on Tuesday. The rally continued in Tuesday’s after-hours session, with shares jumping another 70% to become the session’s top after-hours gainer. 

WOK AI Healthcare Deal Fuels Rally

The rally accelerated after Work Medical said on Monday that it had struck a deal with Shanghai Novabioplus Biotechnology to develop AI-based healthcare and drug discovery systems using biological datasets. The two companies plan to combine Work Medical’s healthcare AI tech with Novabioplus’ protein research databases and lab platforms to build advanced medical models and improve biotech research and development.

According to the company, the partnership strengthens its broader “Healthcare + Web3 + AI” strategy, particularly in biopharmaceutical research. The collaboration includes four major AI-focused projects involving protein structure design, antibody optimization, enzyme engineering and peptide development. The companies said the goal is to use AI to analyze complex biological data, improve molecular design and speed up parts of the drug discovery process.

Work Medical said that the partnership could also support the development of AI-assisted protein and antibody therapies by combining its AI algorithms with Novabioplus’ protein datasets and biological research infrastructure.

Work Medical’s ‘BioToken’ Push 

WOK shares drew particular attention after the company introduced the concept of “BioTokens,” blockchain-based digital assets tied to biological datasets and protein therapeutics. Work Medical said that the deal with Novabioplus aims to generate AI-driven multimodal biological data “BioTokens” by integrating protein sequences, functional biological data and laboratory datasets into AI models for protein molecular design.

The company said the platform is expected to optimize protein structures and improve biological functions, while generating digital biological assets with “assetization potential.” According to Work Medical, the BioToken model could transform biopharmaceutical research outputs into “verifiable and measurable digital assets.”

WOK Deepens Web3 Strategy

The latest AI-biotech announcement comes after several blockchain and tokenization initiatives unveiled by the company this year. Earlier this month, Work Medical said it had been formally awarded a Council Member certificate as a Vice President Unit of the Hong Kong Web3.0 Standardization Association, an organization focused on Web3 standardization research.

The announcement came after Hong Kong implemented its stablecoin regulatory framework in August 2025, which Work Medical said accelerated interest among Chinese-listed companies exploring blockchain integration and asset tokenization. Work Medical said it has been advancing a broader strategy involving healthcare real-world asset tokenization, AI Agent-to-Agent payments and stablecoin-enabled cross-border settlement systems to create digital infrastructure for medical assets.

The company added that it contributed to an Asset Tokenization Whitepaper released during the Web3.0 Standardization and Globalization Summit in Hong Kong in April. According to Work Medical, the whitepaper established foundational standards for industrial asset digitization and compliance frameworks for healthcare-related digital assets.

Work Medical said the company is transitioning from a traditional medical consumables supplier into a builder of “next-generation medical infrastructure powered by AI and blockchain.”

AI Blood Analyzer Added Early Buzz

Investor interest in Work Medical’s AI ambitions had already started building late last year after the commercialization rollout of its AI-Automated Blood Cell Morphology Analyzer in China. In December, the company said that its unit, Hunan Saitumofei Medical Treatment Technology, had entered into a one-year exclusive distribution agreement with Shanghai Benke Medical Technology to distribute the analyzer throughout East China in 2026.

The agreement covered Jiangsu Province, Shanghai Municipality and Zhejiang Province and included a minimum annual sales target of 10 million yuan ($1.5 million). The analyzer received Class II medical device manufacturing approval from Chinese regulators in November and uses AI-driven automation and high-resolution digital imaging technology to identify and classify blood cells.

According to the company, the system can process up to 150 samples at a time, identify 17 different types of white blood cells and analyze a blood smear in about three minutes on average. Work Medical said the analyzer can store over 350,000 high-definition blood cell images and uses AI-based image analysis tech to make results easier for medical professionals to interpret, while helping reduce potential diagnostic risks.

How Do Retail Traders Feel About WOK?

On Stocktwits, retail sentiment for WOK was ‘extremely bullish’ amid a massive 34,275% surge in message volumes over the past three months. The stock’s retail watcher base has also jumped 30% in a week. 

One user outlined their trading strategy and said, “Out at $9, will look for re-entry tomorrow, but this thing has been wildddd. Up 4,500% since lows of yesterday.”

Another user said WOK stock could “just run the rest of the week” and compared the rally to an earlier surge in cannabis company AKAN. 

WOK stock crashed 99.9% over the past year, but surged 206% since January. 

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Read Next: SLS Stock Pops Big After Hours On Imminent Leukemia Trial Data Readout Optimism